LICATA, Anna
 Distribuzione geografica
Continente #
NA - Nord America 19.268
EU - Europa 9.128
AS - Asia 7.491
SA - Sud America 1.212
Continente sconosciuto - Info sul continente non disponibili 1.094
AF - Africa 268
OC - Oceania 29
Totale 38.490
Nazione #
US - Stati Uniti d'America 18.840
IT - Italia 2.567
SG - Singapore 2.532
RU - Federazione Russa 2.443
CN - Cina 1.969
BR - Brasile 904
HK - Hong Kong 900
FI - Finlandia 881
DE - Germania 689
VN - Vietnam 650
PL - Polonia 445
GB - Regno Unito 396
UA - Ucraina 373
FR - Francia 346
IE - Irlanda 342
BD - Bangladesh 290
CA - Canada 214
JP - Giappone 209
IN - India 207
SE - Svezia 165
KR - Corea 155
NL - Olanda 109
MX - Messico 100
TR - Turchia 98
AR - Argentina 70
RO - Romania 67
ES - Italia 64
AT - Austria 58
EC - Ecuador 55
IQ - Iraq 55
ZA - Sudafrica 53
MA - Marocco 50
ID - Indonesia 47
BE - Belgio 44
VE - Venezuela 44
CO - Colombia 43
PK - Pakistan 40
CL - Cile 39
UZ - Uzbekistan 37
CI - Costa d'Avorio 32
IR - Iran 30
PH - Filippine 30
KE - Kenya 28
MY - Malesia 27
EG - Egitto 26
AZ - Azerbaigian 25
CZ - Repubblica Ceca 24
NP - Nepal 24
SA - Arabia Saudita 24
AE - Emirati Arabi Uniti 23
DZ - Algeria 22
JM - Giamaica 22
AU - Australia 19
CR - Costa Rica 18
JO - Giordania 17
PE - Perù 16
PY - Paraguay 16
BG - Bulgaria 15
KZ - Kazakistan 15
CH - Svizzera 14
TH - Thailandia 14
BO - Bolivia 13
HN - Honduras 13
EU - Europa 12
LB - Libano 12
TN - Tunisia 12
ET - Etiopia 11
LT - Lituania 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
RS - Serbia 10
GT - Guatemala 9
AL - Albania 8
BB - Barbados 8
PA - Panama 8
TW - Taiwan 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
EE - Estonia 7
NI - Nicaragua 7
QA - Qatar 7
SN - Senegal 7
SV - El Salvador 7
BH - Bahrain 6
GR - Grecia 6
HU - Ungheria 6
IL - Israele 6
AO - Angola 5
DK - Danimarca 5
SI - Slovenia 5
AM - Armenia 4
BN - Brunei Darussalam 4
BY - Bielorussia 4
CY - Cipro 4
OM - Oman 4
PS - Palestinian Territory 4
TG - Togo 4
XK - ???statistics.table.value.countryCode.XK??? 4
GA - Gabon 3
GE - Georgia 3
Totale 37.352
Città #
Ashburn 2.208
Fairfield 2.049
Singapore 1.715
San Jose 1.469
Chandler 1.010
Woodbridge 951
Seattle 806
Houston 793
Wilmington 782
Cambridge 688
Hong Kong 670
Ann Arbor 500
Council Bluffs 493
Palermo 424
Zgierz 384
Dublin 341
Beijing 338
Moscow 336
Los Angeles 322
New York 274
Medford 269
Helsinki 232
Ho Chi Minh City 232
Des Moines 231
Santa Clara 230
Altamura 210
Boardman 198
Nanjing 195
Tokyo 182
Jacksonville 179
Princeton 173
Lauterbourg 171
Milan 164
Hanoi 160
The Dalles 159
Dallas 151
Lawrence 150
Frankfurt am Main 145
San Diego 135
Chicago 118
Rome 112
Dearborn 106
Hefei 103
Buffalo 94
Jinan 91
Sunnyvale 89
São Paulo 89
Phoenix 79
London 75
Tulsa 75
Nanchang 73
Shenyang 71
Nuremberg 68
Orem 65
Tianjin 59
Atlanta 56
Changsha 55
Ludwigshafen am Rhein 55
Columbus 54
Hebei 53
Munich 49
Naples 48
Amsterdam 47
Izmir 47
Springfield 46
Toronto 46
Guangzhou 44
Warsaw 43
Brooklyn 42
Brussels 42
Mumbai 41
Ningbo 41
Jiaxing 40
Zhengzhou 37
Chennai 36
Denver 35
Montreal 35
Redwood City 35
Da Nang 33
Falls Church 33
Abidjan 32
Vienna 31
Johannesburg 30
Brasília 29
Casablanca 28
Manchester 28
Washington 28
Florence 27
Kumar 27
San Paolo di Civitate 27
Haiphong 26
Seongnam 26
Verona 26
Bremen 25
Stockholm 25
Hangzhou 24
Mexico City 24
Poplar 24
Saint Petersburg 24
Lappeenranta 23
Totale 23.113
Nome #
MODIFICAZIONI ECOGRAFICHE DELLA LINFADENOPATIA DELL’ILO EPATICO DOPO ERADICAZIONE DELL’HCV CON DIRECT-ACTING ANTIVIRALS 568
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 502
A phenobarbital overdose: a case report 431
PRESENTAZIONE ECOGRAFICA DELL’EPATOCARCINOMA: ESPERIENZA DI UN SINGOLO CENTRO NELL’ARCO DI TRE DECENNI 430
Clinical manifestations and outcome predictors of SARS-COV2 disease (COVID-19): experience of a single center. 415
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 347
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 338
Clinical course and management of acute and chronic viral hepatitis during pregnancy. 333
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 321
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 315
Early carotid atherosclerosis and cardiac diastolic abnormalities in hypertensive subjects 308
Clinical course and genetic susceptibility of primary biliary cirrhosis: Analysis of a prospective cohort 308
Clinical implications of the hyperdynamic syndrome in cirrhosis. 288
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 286
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 286
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 282
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 282
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 280
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 277
EFFETTI DELLA TERAPIA CON DIRECT ACTING ANTIVIRALS (DAAS) SUI PARAMETRI ECOGRAFICI DI IPERTENSIONE PORTALE 273
Surveillance program for diagnosis of hcc in liver cirrhosis: Role of ultrasound echo patterns 271
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. 270
C4BQ0: a genetic marker of familial HCV-related liver cirrhosis. 266
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 266
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract 266
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 264
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 261
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 259
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 259
Elderly Onset Celiac Disease: A Narrative Review. 258
Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data 255
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 254
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 254
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 253
Acute hepatitis C: in search of the optimal approach to cure. 253
Clinical trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. 253
Nontumorous portal vein thrombosis in liver cirrhosis: Possible role of β-blockers 251
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 246
Plasma adiponectin: A contributing factor for cardiac changes in visceral obesity-associated hypertension 246
Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases 241
Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study 241
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis 239
A patient with acute hepatitis C and possible IFN toxicity [2] 239
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. 238
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 238
The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center 238
Inflammation and Aortic Stiffness: An Individual Participant Data Meta-Analysis in Patients With Inflammatory Bowel Disease. 238
Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma 238
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. 237
Genetic predisposition to thrombophilia in inflammatory bowel disease 237
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 233
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 233
DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINS INTERACTION: A CASE REPORT 232
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. 229
A woman with a long history of abdominal pain 227
Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects 226
A Case of Fatal Drug Rash Eosinophilia and Systemic Symptoms from Allopurinol 222
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 222
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 221
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 221
Cardiac involvement in rheumatoid arthritis: evidence of silent heart disease 219
Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients 219
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 219
Effetti cardioprotettivi del Blocco del Sistema Renina-Angiotensina-Aldosterone tramite l’associazione ACE-inibitore – Sartani: Relazione con i livelli circolanti di Transforming Growth Factor ß1. 216
Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult 214
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 213
Epidemiology, Diagnosis, and Non-Pharmacological Treatment of HCC 212
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 212
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 212
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. 211
Fluoroquinolone-induced liver injury: three new cases and a review of the literature. 211
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 210
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies 210
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 209
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 209
Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance 208
Is vitamin D deficiency predictor of complications development in patients with HCV-related cirrhosis? 207
COMEPA (COVID-19 Medicina Policlinico Palermo): a study in hospitalized patients. 207
AISF position paper on liver disease and pregnancy. 204
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 204
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 203
Lymphocyte beta-adrenergic receptors in young subjects with peripheral or central obesity: relationship with central haemodynamics and left ventricular function 203
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center 203
Meccanismi immunologici e molecolari del danno epatico da farmaci 202
Cardiac involvement in patients with cirrhosis: a focus on clinical features and diagnosis 202
Treatment of hepatitis C: critical appraisal of the evidence 201
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 201
When and how to treat acute hepatitis C? 200
Prognostic indicators of successful endoscopic sclerotherapy for prevention of rebleeding from oesophageal varices in cirrhosis: a long-term cohort study. 199
Optimizing diagnostic approach to drug-induced liver injury 197
A questionable diagnosis in a woman with drowsiness 197
Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study 196
Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal 196
A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort 196
Association between reduced lymphocyte beta-adrenergic receptors and left ventricular dysfunction in young obese subjects 195
Patologie da sovraccarico di ferro:recenti acquisizioni 194
Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor beta1. 194
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 193
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 190
Liver function test abnormalities in patients with inflammatory bowel diseases: A hospital-based survey 189
Totale 24.842
Categoria #
all - tutte 129.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.802


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.664 0 0 0 100 87 109 131 165 284 261 177 350
2022/20233.256 277 599 47 332 273 455 228 444 335 52 130 84
2023/20241.552 68 178 81 113 118 337 153 98 73 87 74 172
2024/20253.634 113 237 181 304 156 134 234 220 289 443 531 792
2025/202613.457 812 341 679 1.071 1.291 1.966 1.950 1.413 1.237 1.407 678 612
2026/20272.803 716 488 1.571 28 0 0 0 0 0 0 0 0
Totale 38.490